Oligometastatic breast cancer is a condition in which breast cancer has spread to a small number of other parts of the body. Patients with this type of disease may live longer than those with more widespread metastases. In addition to standard treatments that act on the whole body, such as chemotherapy or hormonal therapy, these patients might also benefit from local treatments that directly target the cancer spots. One of these local treatments is stereotactic body radiotherapy (SBRT), a non-invasive radiation treatment that delivers high doses of radiation in a few sessions. In the past, most of the evidence about the benefit of local treatments came from surgery. More recently, there has been growing interest in SBRT because it does not require surgery. However, the results of studies so far have not been consistent.The goal of this multicenter retrospective study is to better understand whether SBRT can improve disease control and survival in patients with breast cancer that has spread to a limited number of sites outside the brain.
Study Type
OBSERVATIONAL
Enrollment
300
Aorn San Pio
Benevento, Benevento, Italy
NOT_YET_RECRUITINGHumanitas Gavazzeni
Bergamo, Bergamo, Italy
RECRUITINGOspedale Perrino
Brindisi, BR, Italy
NOT_YET_RECRUITINGSpedali Civili
Brescia, BS, Italy
RECRUITINGResponsible Research Hospital
Campobasso, CB, Italy
RECRUITINGAzienda Ospedaliera Universitaria Careggi
Florence, Firenze, Italy
NOT_YET_RECRUITINGIrccs Ospedale Policlinico San Martino
Genova, Genova, Italy
NOT_YET_RECRUITINGA.O.U. "G. Martino" - Università degli Studi di Messina
Messina, Messina, Italy
NOT_YET_RECRUITINGFondazione I.R.C.C.S Istituto Nazionale Tumori di Milano
Milan, MILANO, Italy
RECRUITINGIEO
Milan, Milano, Italy
NOT_YET_RECRUITING...and 18 more locations
progression free survival
years of survival without disease progression assessed by imaging
Time frame: from January 2010 to December 2023
Local Control
time between treatment and disease recurrence assessed by imaging
Time frame: from January 2010 to December 2023
overall survival
the time from diagnosis or initiation of treatment until death from any cause
Time frame: From January 2010 to December 2023
acute and late toxicity RT related
Evaluation of toxicities related to radiotherapy treatment using the scale CTCAE (Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening, Grade 5: Death)
Time frame: from January 2010 to December 2023
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.